Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations

Shakhova, 2012, Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma, Nat Cell Biol, 14, 882, 10.1038/ncb2535 Omholt, 2011, KIT pathway alterations in mucosal melanomas of the vulva and other sites, Clin Cancer Res, 17, 3933, 10.1158/1078-0432.CCR-10-2917 Schoenewolf, 2012, Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations, Eur J Cancer, 48, 1842, 10.1016/j.ejca.2012.02.049 Van Raamsdonk, 2009, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, 457, 599, 10.1038/nature07586 Van Raamsdonk, 2010, Mutations in GNA11 in uveal melanoma, N Engl J Med, 363, 2191, 10.1056/NEJMoa1000584 Krauthammer, 2012, Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nat Genet, 44, 1006, 10.1038/ng.2359 Hodis, 2012, A landscape of driver mutations in melanoma, Cell, 150, 251, 10.1016/j.cell.2012.06.024 Huang, 2013, Highly recurrent TERT promoter mutations in human melanoma, Science, 339, 957, 10.1126/science.1229259 Dummer, 2013, Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.9028 Bollag, 2010, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, 467, 596, 10.1038/nature09454 Kefford, 2010, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.8503 Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011 Long, 2012, Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 1087, 10.1016/S1470-2045(12)70431-X Ribas, 2011, Brim 2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive metastatic melanoma, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.8509 Sosman, 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, 366, 707, 10.1056/NEJMoa1112302 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Chapman, 2012, Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma, J Clin Oncol, 10.1200/jco.2012.30.15_suppl.8502 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Long, 2010, Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets), Ann Oncol, 21 Pratilas, 2009, (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway, Proc Natl Acad Sci U S A, 106, 4519, 10.1073/pnas.0900780106 Kirkwood, 2012, Phase II, open-label, randomized trial of the MEK1/2 Inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma, Clin Cancer Res, 18, 555, 10.1158/1078-0432.CCR-11-1491 Middleton, 2013, Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.9004 Carvajal, 2013, Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM), J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.cra9003 Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, 367, 1694, 10.1056/NEJMoa1210093 Lito, 2012, Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas, Cancer Cell, 22, 668, 10.1016/j.ccr.2012.10.009 Ascierto, 2013, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study, Lancet Oncol, 14, 249, 10.1016/S1470-2045(13)70024-X Margolin, 2012, Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial, Lancet Oncol, 13, 459, 10.1016/S1470-2045(12)70090-6 Dummer, 2012, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, 10.1093/annonc/mds229 Rinderknecht, 2013, RASopathic skin eruptions during vemurafenib therapy, PLoS One, 3, e58721, 10.1371/journal.pone.0058721 Anforth, 2012, Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, Br J Dermatol, 167, 1153, 10.1111/j.1365-2133.2012.11155.x Dummer, 2012, Ultraviolet A and photosensitivity during vemurafenib therapy, N Engl J Med, 366, 480, 10.1056/NEJMc1113752 Adjei, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers, J Clin Oncol, 26, 2139, 10.1200/JCO.2007.14.4956 Eggmann, 2012, Self limiting serous retinopathy-like toxicity during MEK kinase inhibition, EADO, P32 Belloni, 2012, Cutaneous drug eruptions associated with the use of new oncological drugs, Chem Immunol Allergy, 97, 191, 10.1159/000335632 Schad, 2010, Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders, Clin Cancer Res, 16, 1058, 10.1158/1078-0432.CCR-09-1766 Dummer, 2012, Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights, Curr Opin Oncol, 24, 150, 10.1097/CCO.0b013e32834fca92 Das Thakur, 2013, Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, 494, 251, 10.1038/nature11814 Hodi, 2008, Major response to imatinib mesylate in KIT-mutated melanoma, J Clin Oncol, 26, 2046, 10.1200/JCO.2007.14.0707 Curtin, 2006, Somatic activation of KIT in distinct subtypes of melanoma, J Clin Oncol, 24, 4340, 10.1200/JCO.2006.06.2984 Carvajal, 2011, KIT as a therapeutic target in metastatic melanoma, JAMA, 305, 2327, 10.1001/jama.2011.746 Guo, 2011, Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification, J Clin Oncol, 29, 2904, 10.1200/JCO.2010.33.9275